Tirzepatide for the Treatment of Cannabis Use Disorder

Sponsor
Brigham and Women's Hospital
Study ID
NCT07265752
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cannabis Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    2.5mg subcutaneous injection once
  • Placebo — DRUG
    Saline placebo subcutaneous injection once

Study Details

This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.

Key Dates

Start date
Jul 1, 2026
Status verified
Dec 2025
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
6 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: tirzepatide
    2.5mg subcutaneous injection once
  • Placebo Comparator: placebo
    matching placebo subcutaneous injection once

Primary Outcome Measure

Cue-Induced Craving [ Time Frame: 5 weeks ]

Central Contacts

Related Studies